Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q16824572> ?p ?o }
Showing triples 1 to 36 of
36
with 100 triples per page.
- Q16824572 subject Q52376.
- Q16824572 subject Q6814466.
- Q16824572 subject Q7164711.
- Q16824572 subject Q8593001.
- Q16824572 subject Q8808791.
- Q16824572 subject Q8969064.
- Q16824572 abstract "Paritaprevir (ABT-450) is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.p. 248Paritaprevir is a component of Viekira Pak and Technivie.".
- Q16824572 thumbnail Paritaprevir_structure_2.svg?width=300.
- Q16824572 wikiPageWikiLink Q14864419.
- Q16824572 wikiPageWikiLink Q154869.
- Q16824572 wikiPageWikiLink Q17912018.
- Q16824572 wikiPageWikiLink Q19462214.
- Q16824572 wikiPageWikiLink Q19598175.
- Q16824572 wikiPageWikiLink Q19858657.
- Q16824572 wikiPageWikiLink Q306764.
- Q16824572 wikiPageWikiLink Q420032.
- Q16824572 wikiPageWikiLink Q421862.
- Q16824572 wikiPageWikiLink Q422618.
- Q16824572 wikiPageWikiLink Q52376.
- Q16824572 wikiPageWikiLink Q616005.
- Q16824572 wikiPageWikiLink Q6814466.
- Q16824572 wikiPageWikiLink Q6955241.
- Q16824572 wikiPageWikiLink Q6955244.
- Q16824572 wikiPageWikiLink Q708693.
- Q16824572 wikiPageWikiLink Q7164711.
- Q16824572 wikiPageWikiLink Q8593001.
- Q16824572 wikiPageWikiLink Q8808791.
- Q16824572 wikiPageWikiLink Q8969064.
- Q16824572 type ChemicalSubstance.
- Q16824572 type Drug.
- Q16824572 type ChemicalObject.
- Q16824572 type Thing.
- Q16824572 type Q8386.
- Q16824572 comment "Paritaprevir (ABT-450) is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1.".
- Q16824572 label "Paritaprevir".
- Q16824572 depiction Paritaprevir_structure_2.svg.